Volume shows that nobody has yet bitten the bullet...

Any option traders on the board?

This might be old press release, but reposting to refresh memory of those who are probably new to mnkd.

http://www.news.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-newsArticle&ID=1128018&highlight=

As per Apr 10, 2008 press release, management basically states that there will be no partnership until they are able to validate efficacy and safety of TI upon Phase 3 trial data. Maybe this is an all together different clinical study, but the 2 ongoing trials do feed into the complete data MNKD hopes to present to potential partners.

But, well, the big picture is, mnkd management thinks that it is hard to put a value on their invention unless they are able to demonstrate complete trial data - which, by the way, is fair enough considering that they might be solving something that others have failed to in the past. Usually such pharma breakthroughs are much better valued when all the fact set is presented (case in point - Byudereon)

I don't mind being pleasantly surprised with some positive catalyst, but I believe we are not going to see any partnership until trial data from all current trials (171, 175) are available.

For those of you who are interested in general biological science/recent advancements in genetical research on diabetes and insulin resistance...

http://www.sciencedaily.com/releases/2012/09/120912184512.htm

I'm very well aware of Martin Shkreli actions on mnkd as well as FDA insider trading etc. Yes, he did send a detailed memo to FDA prior to approval. But if you think FDA did a complete turn-around purely based on his letter, you are falling prey to stupid conspiracy theories espoused by random blog writers. Lol, FDA is not a random body who gets swayed by shorties out there...and there is absolutely no inkling of proof that it would have accepted Afrezza otherwise.

A single CRL is like a life or death for many biotechs out there...ends up costing 10's if not 100's of millions until the next resubmission. I don't think AlMann would have meekly accepted a weak answer from FDA. Please do not base your approval theory on this alone. Yes, there are merits to this drug and the trials 171 and 177 are proof itself on the drug labeling and direction.

By simple law of noncontradiction, if Afrezza science was slam dunk, we (neither big pharma) would not be sitting here speculating on various things. I don't mean to say it doesn't work...maybe we get more data to prove that it does great things...but as of today that isn't the case, if it were so, it would have been a landrush given that we are addressing the epidemic diabetic market. You see what I mean?

Agains, it is at best laughable to say "he is no longer investing" and "his value is dimished", when he is already $1B deep, sure he is not throwing in more dimes in the pool :-).

Your statement about science is valid for every biotech out there...inherently they all work on science - thats the nature of this sector and each one is trying to solve their own niche research area. We are not talking of marketing firms here, but to discern science that works or not, is what we investors lack, and only the scientists working in the program would know. We simply believe the story told to us and take into account (atleast me) AlMann faith in the program and throw in our savings.

Maybe he is impediment to partnership, but I trust that he is doing the best for himself and the company rather than big pharma. Let me ask you this, do you think we'd see great products from Apple now that the great soul Steve Jobs is gone? The genetical code of the company lies with the founder and especially those who have been successful serial enterpreneurs.

Until then, I like the small pop we have experienced the last few day and hoping for it to translate to a significant one on any good news.

I adore AlMann and truly wish him well. But I would be the first to head to the exit if AlMann is no more. Companies are built on a person's charisma, will and the drive to achieve great things. AlMann comes from that camp, and I'm invested in MNKD mostly due to his skin in the game than about the biokinectics of the afrezza molecule or whatever. Sure if Afrezza benefits diabetics, great! But honestly speaking, no one on this board know anything about efficacy or trial results.

Been reading about your Jan 13 call options, I would say it would be unwise to hold on to it any longer. We will see a dilution and probably get to experience yet another price drop (though I think it might not be substantial enough to retest 1.5's pps level). Recoup some money while we are riding this "unwarranted" pop the last few days. Warrants are ok if they have liquidity, but they trade very thin on MNKD. You'd be better off holding stocks than options/warrants. Try to slowly recoup losses writing covered calls.

Good luck to you!